Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases

Hepatology Research

Volumn 43, Issue 11, 2013, Pages 1182-1189

  Masaki, Keiichi ^a   Takaki, Shintaro ^a   Hyogo, Hideyuki ^a   Kobayashi, Tomoki ^a   Fukuhara, Takayuki ^a   Naeshiro, Noriaki ^a   Honda, Yoji ^a   Nakahara, Takashi ^a   Ohno, Atsushi ^a   Miyaki, Daisuke ^a   Murakami, Eisuke ^a   Nagaoki, Yuko ^a   Kawaoka, Tomokazu ^a   Tsuge, Masataka ^a   Hiraga, Nobuhiko ^a   Hiramatsu, Akira ^a   Imamura, Michio ^a   Kawakami, Yoshiiku ^a   Aikata, Hiroshi ^a   Ochi, Hidenori ^a   Takahashi, Shoichi ^a   Arihiro, Koji ^a   Chayama, Kazuaki ^a   more..

^a HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Controlled attenuation parameter; FibroScan; Liver steatosis; Non invasively diagnose

Indexed keywords

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHRONIC LIVER DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED ATTENUATION PARAMETER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FATTY LIVER; FEMALE; HEPATOBILIARY PARAMETERS; HUMAN; HUMAN TISSUE; JAPANESE; LIVER; LIVER BIOPSY; LIVER CELL; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SPLEEN;

EID: 84886845021     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12094     Document Type: Article

References (50)

1. Eguchi Y, Hyogo H, Ono M etal. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol 2012; 47: 586-595.
2. Yoneda M, Imajo K, Eguchi Y etal. Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels. J Gastroenterol 2012. In press.
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
4. Liou I, Kowdley KV. Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006; 40 (Suppl 1): S11-16.
5. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol. 2010; 5: 145-171.
6. Akuta N, Suzuki F, Hirakawa Y etal. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan:amino acid substututions in HCV core region as predictor of sustained virological response. J Med Virol 2009; 81: 452-458.
7. Akuta N, Suzuki F, Kawamura Y etal. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 2007; 79: 1686-1695.
8. Akuta N, Suzuki F, Kawamura Y etal. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b:amino acid substitutions in the core region and low density lipoprotein cholesterol levels. J Hepatol 2007; 46: 403-410.
9. Akuta N, Suzuki F, Kawamura Y etal. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervilorogy 2007; 50: 361-368.
10. Kitamura S, Tsuge M, Hatakeyama T etal. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrese with pegylated interferon plus ribavirin therapy. Antivir Ther 2010; 15: 1087-1097.
11. Okanoue T, Itoh Y, Hashimoto H etal. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C:a Japanese multi-center study. J Gastroenterol 2009; 44: 952-963.
12. Oshita A, Tashiro H, Amano H etal. Safety and feasibility of diet-treated donors with steatotic livers at the initial consultation for living-donor liver transplantation. Transplantation 2012; 93: 1024-1030.
13. Adam R, Hoti E. Liver transplantation: the current situation. Semin Liver Dis 2009; 29: 3-18.
14. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-1362.
15. Ratziu V, Chalotte F, Heurtier A etal. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-1906.
16. Merriman RB, Ferrell LD, Patti MG etal. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006; 44: 874-880.
17. Castera L. Non-invasive diagnosis of steatosis and fibrosis. Diabetes Metab 2008; 34: 674-679.
18. Sasso M, Beaugrand M, de Ledinghen V etal. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010; 36: 1825-1835.
19. Sasso M, Miette V, Sandrin L, Beaugrand M. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol 2012; 36 (1): 13-20.
20. Myers RP, Pollett A, Kirsch R etal. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int 2012; 32: 902-910.
21. Sandrin L, Tanter M, Gennisson JL, Catheline S, Fink M. Shear elasticity probe for soft tissues with 1-D transient elastography. IEEE Trans Ultrason Ferroelectr Freq Control 2002; 49: 436-446.
22. Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992; 15: 572-577.
23. Kleiner DE, Brunt EM, Van Natta M etal. Design and validation of histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
24. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
25. Umemura T, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res 2007; 37 (Suppl 2): S95-S100.
26. Okanoue T, Umemura A, Yasui K, Itoh Y. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. J Gastroenterol Hepatol 2011; 26 (Suppl 1): 153-162.
27. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-S112.
28. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004; 126: 586-597.
29. Ratziu V, Charlotte F, Heurtier A etal. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-1906.
30. Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British society of Gastroenterology. Gut 1999; 45 (Suppl 4): IV1-IV11.
31. Guha IN, Myers RP, Patel K, TalWalkar JA. Biomarkers of liver fibrosis: what lies beneth the receiver operating characteristic curve? Hepatology 2011; 54: 1454-1462.
32. Mazhar SM, Shiehmorteza M, Sirlin CB etal. Noninvasive assessment of hepatic steatosis. Clin Gastroenterol Hepatol 2009; 7: 135-140.
33. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009; 51: 433-445.
34. Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis 2007; 11: 37-54, viii.
35. Sandrin L, Fourquet B, Hasquenoph JM etal. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-1713.
36. De Ledinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012; 32: 911-918.
37. Sasso M, Tengher-Bama I, Zoil M etal. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan®: validation in chronic hepatitis C. J Viral Hepat 2012; 19: 244-253.
38. Friedrich-Rust M, Romen D, Vermehren J etal. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol 2012; 81: 325-331.
39. Goldaracena N, Quinonez E, Mendez P etal. Extremely marginal liver grafts from deceased donors have outcome similar to ideal grafts. Transplant Proc 2012; 44: 2219-2222.
40. Todo S, Demetris AJ, Makowka L etal. Primary nonfunction of hepatic allografts with preexisting fatty infiltration. Transplantation 1989; 47: 903.
41. D'Alessandro AM, Kalayoglu M, Sollinger HW etal. The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation. Transplantation 1991; 51: 157.
42. Ploeg RJ, D'Alessandro AM, Knechtle SJ etal. Risk factors for primary dysfunction after liver transplantation - A multivariate analysis. Transplantation 1993; 55: 807.
43. Marsman WA, Wiesner RH, Rodriguez L etal. Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation 1996; 62: 1246.
44. Imber CJ, St Peter SD, Handa A, Friend PJ. Hepatic steatosis and its relationship to transplantation. Liver Transpl 2002; 8: 415.
45. Seifalian AM, Chidambaram V, Rolles K, Davidson BR. In vivo demonstration of impaired microcirculation in steatotic human liver grafts. Liver Transplant Proc 1999; 31: 403.
46. Fukumori T, Ohkohchi N, Tsukamoto S, Satomi S. The mechanism of injury in a steatotic liver graft during cold preservation. Transplantation 1999; 67: 195.
47. Nagai S, Fujimoto Y, Kamei H, Nakamura T, Kiuchi T. Mild hepatic macrovesicular steatosis may be a risk factor for hyperbilirubinaemia in living liver donors following right hepatectomy. Br J Surg 2009; 96: 437-444.
48. Fan ST, Lo CM, Liu CL, Yong BH, Chan JK, Ng IO. Safety of donors in live donor liver transplantation using right lobe grafts. Arch Surg 2000; 135: 336-340.
49. Oliva MR, Mortele KJ, Segatto E etal. Computed tomography features of nonalcoholic steatohepatitis with histopathologic correlation. J Comput Assist Tomogr 2006; 30 (1): 37-43.
50. Siegelman ES, Rosen MA. Imaging of hepatic steatosis. Semin Liver Dis 2001; 21: 71-80.